HC Wainwright reaffirmed their buy rating on shares of Paratek Pharmaceuticals (NASDAQ:PRTK) in a research report released on Wednesday, June 26th, AnalystRatings.com reports.
“We view the promotion of Dr. Loh as particularly well-deserved and quite likely to be broadly well-received by investors and other constituents. Affirm Buy.”,” HC Wainwright’s analyst commented.
Other equities research analysts have also recently issued research reports about the company. Canaccord Genuity set a $40.00 price target on Mallinckrodt and gave the company a buy rating in a report on Monday, March 18th. Wedbush lifted their price target on Roku from $55.00 to $65.00 and gave the stock a neutral rating in a report on Thursday, May 9th. LADENBURG THALM/SH SH reissued a buy rating on shares of Paratek Pharmaceuticals in a report on Thursday, May 9th. Zacks Investment Research cut HEXO from a hold rating to a sell rating in a research report on Wednesday, May 15th. Finally, ValuEngine cut Zosano Pharma from a buy rating to a hold rating in a research report on Wednesday, May 1st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. Paratek Pharmaceuticals currently has a consensus rating of Hold and an average price target of $22.25.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.19) by $0.09. The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.89 million. Paratek Pharmaceuticals had a negative return on equity of 232.61% and a negative net margin of 642.70%. Analysts expect that Paratek Pharmaceuticals will post -4.39 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in PRTK. BNP Paribas Arbitrage SA acquired a new stake in shares of Paratek Pharmaceuticals during the 1st quarter worth $36,000. Hsbc Holdings PLC bought a new stake in shares of Paratek Pharmaceuticals during the fourth quarter valued at approximately $59,000. Annex Advisory Services LLC raised its holdings in shares of Paratek Pharmaceuticals by 15.3% during the fourth quarter. Annex Advisory Services LLC now owns 15,100 shares of the specialty pharmaceutical company’s stock valued at $77,000 after buying an additional 2,000 shares during the last quarter. Stifel Financial Corp acquired a new position in shares of Paratek Pharmaceuticals during the fourth quarter valued at approximately $90,000. Finally, Telemetry Investments L.L.C. acquired a new position in Paratek Pharmaceuticals in the fourth quarter worth approximately $113,000. Institutional investors and hedge funds own 75.04% of the company’s stock.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
See Also: What is the cash asset ratio?
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.